Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKß/NF-κB signaling pathway in lung cancer cells

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Yu, Zhenlong ^a   Guo, Wei ^a   Ma, Xiaochi ^a   Zhang, Baojing ^a   Dong, Peipei ^a   Huang, Lin ^a   Wang, Xiuli ^a   Wang, Chao ^a   Huo, Xiaokui ^a   Yu, Wendan ^a   Yi, Canhui ^a   Xiao, Yao ^a   Yang, Wenjing ^a   Qin, Yu ^a   Yuan, Yuhui ^a   Meng, Songshu ^a   Liu, Quentin ^a,b   Deng, Wuguo ^a,b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

COX 2; Gamabufotalin; IKK ; NF B; NSCLC; p300

Indexed keywords

BUFADIENOLIDE DERIVATIVE; CASPASE; CYCLOOXYGENASE 2; CYTOCHROME C; E1A ASSOCIATED P300 PROTEIN; GAMABUFOTALIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AMPHIBIAN VENOM; BUFOTALIN; PTGS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MOLECULAR DOCKING; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION; PROTEIN CONFORMATION; TUMOR CELL LINE;

AMPHIBIAN VENOMS; ANIMALS; BUFANOLIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN CONFORMATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908066228     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-203     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
4. Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005, 229:157-169.
5. Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
6. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995, 267:1485-1488.
7. Ling J, Kumar R: Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett 2012, 322:119-126.
8. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV: Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 2005, 18:221-227.
9. Wang D, Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29:781-788.
10. Guillem-Llobat P, Dovizio M, Alberti S, Bruno A, Patrignani P: Platelets, cyclooxygenases, and colon cancer. Semin Onco 2014, 41:385-396.
11. Grimminger PP, Stohlmacher J, Vallbohmer D, Schneider PM, Holscher AH, Metzger R, Danenberg PV, Brabender J: Prognostic significance and clinicopathological associations of COX-2 SNP in patients with nonsmall cell lung cancer. J Oncol 2009, 2009:139590.
12. Marks F, Muller-Decker K, Furstenberger G: A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology 2000, 153:11-26.
13. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007, 121:2381-2386.
14. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O'Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM: Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 2004, 25:1517-1524.
15. Nakanishi M, Rosenberg DW: Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 2006, 1761:1335-1343.
16. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM: HER2 and COX2 expression in human prostate cancer. Eur J Cancer 2004, 40:50-55.
17. Shi D, Xiao X, Wang J, Liu L, Chen W, Fu L, Xie F, Huang W, DengW: Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-kappaB, c/EBPbeta, and p300 signaling. J Pineal Res 2012, 53:154-165.
18. Deng WG, Zhu Y, Wu KK: Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004, 103:2135-2142.
19. Li J, Peet GW, Pullen SS, Schembri-King J, Warren TC, Marcu KB, Kehry MR, Barton R, Jakes S: Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha. J Biol Chem 1998, 273:30736-30741.
20. May BH, Lu C, Bennett L, Hugel HM, Xue CC: Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for agerelated dementia and memory impairment. Biogerontology 2012, 13:299-312.
21. Xingping L, Zongde Z, Yanfang Z, Liren C, Yongmin L: Microemulsion electrokinetic chromatographic determination of bufadienolides in toad venom and in traditional Chinese medicine. Anal Bioanal Chem 2006, 384:1254-1258.
22. Chen KK, Kovarikova A: Pharmacology and toxicology of toad venom. J Pharm Sci 1967, 56:1535-1541.
23. The State Pharmacopoeia Commission of People's Republic of China: Pharmacopoeia of the People's Republic of China. Beijing: China Chemical Industry Press; 2010:360.
24. Moreno YBL, Katz A, Miklos W, Cimmino A, Tal DM, Ainbinder E, Zehl M, Urban E, Evidente A, Kopp B, Berger W, Feron O, Karlish S, Kiss R: Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K + -ATPase. Mol Cancer 2013, 12:33.
25. Mori H, Sugie S, Yoshimi N, Hara A, Tanaka T: Control of cell proliferation in cancer prevention. Mutat Res 1999, 428:291-298.
26. Hajra KM, Liu JR: Apoptosome dysfunction in human cancer. Apoptosis 2004, 9:691-704.
27. Kasibhatla S, Tseng B: Why target apoptosis in cancer treatment? Mol Cancer Ther 2003, 2:573-580.
28. Zhou F, Wu S, Wu B, Chen WR, Xing D: Mitochondria-targeting single-walled carbon nanotubes for cancer photothermal therapy. Small 2011, 7:2727-2735.
29. Chun KS, Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100.
30. Kim Y, Fischer SM: Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J Biol Chem 1998, 273:27686-27694.
31. Guo LY, Hung TM, Bae KH, Shin EM, Zhou HY, Hong YN, Kang SS, Kim HP, Kim YS: Anti-inflammatory effects of schisandrin isolated from the fruit of schisandra chinensis baill. Eur J Pharmacol 2008, 591:293-299.
32. Wang YL, He SX, Luo JY: Progress in research on antitumor activity of saikosaponin and its mechanism. Zhong Xi Yi Jie He Xue Bao 2006, 4:98-100.
33. Terness P, Navolan D, Dufter C, Kopp B, Opelz G: The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity. Int Immunopharmacol 2001, 1:119-134.
34. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
35. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996, 56:2556-2560.
36. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
37. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
38. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E: Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004, 10:2694-2704.
39. Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB, Gescher AJ: Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Br J Cancer 2004, 91:1213-1219.
40. Yang CM, Chien CS, Hsiao LD, Luo SF, Wang CC: Interleukin-1beta-induced cyclooxygenase-2 expression is mediated through activation of p42/44 and p38 MAPKS, and NF-kappaB pathways in canine tracheal smooth muscle cells. Cell Signal 2002, 14:899-911.
41. Deng WG, Wu KK: Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol 2003, 171:6581-6588.
42. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M: Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996, 16:1295-1304.
43. Liu S, Misquitta YR, Olland A, Johnson MA, Kelleher KS, Kriz R, Lin LL, Stahl M, Mosyak L: Crystal structure of a human IkappaB kinase beta asymmetric dimer. J Biol Chem 2013, 288:22758-22767.
44. Xu G, Lo YC, Li Q, Napolitano G, Wu X, Jiang X, Dreano M, Karin M, Wu H: Crystal structure of inhibitor of kappaB kinase beta. Nature 2011, 472:325-330.
45. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM: Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999, 284:321-325.
46. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M: The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999, 189:1839-1845.